v3.25.4
Mergers, Acquisition of Opus Genetics, Summary of Transaction (Details)
$ / shares in Units, $ in Millions
Oct. 22, 2024
USD ($)
Asset
$ / shares
shares
Apr. 30, 2025
shares
Common Stock [Member] | Series A Preferred Stock [Member]    
Acquisition of Opus Genetics [Abstract]    
Number of shares issued upon conversion (in shares)   1,000
Opus Genetics, Inc. [Member]    
Acquisition of Opus Genetics [Abstract]    
Number of asset acquired | Asset 1  
Acquisition cost | $ $ 2.8  
Opus Genetics, Inc. [Member] | Maximum [Member]    
Acquisition of Opus Genetics [Abstract]    
Percentage of underlying intellectual property associated with IRD therapies 90.00%  
Opus Genetics, Inc. [Member] | Series A Preferred Stock [Member]    
Acquisition of Opus Genetics [Abstract]    
Shares issued (in shares) 14,145.374  
Shares issued, price per share (in dollars per share) | $ / shares $ 0.0001  
Number of shares issued upon conversion (in shares) 1,000  
Opus Genetics, Inc. [Member] | Common Stock [Member]    
Acquisition of Opus Genetics [Abstract]    
Shares issued (in shares) 5,237,063  
Shares issued, price per share (in dollars per share) | $ / shares $ 0.0001